Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) Price Target at $200.79

Charles River Laboratories International, Inc. (NYSE:CRL) has received a consensus recommendation of “Reduce” from the seventeen analysts that are presently covering the stock, Marketbeat reports. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $200.79.

Several equities research analysts have recently issued reports on the stock. UBS Group reissued a “neutral” rating and set a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Morgan Stanley lowered their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Finally, Bank of America lowered their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th.

Charles River Laboratories International Stock Down 0.5 %

Shares of CRL stock opened at $153.20 on Friday. The firm has a fifty day moving average of $177.23 and a 200-day moving average of $191.71. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 12-month low of $150.79 and a 12-month high of $275.00. The company has a market capitalization of $7.83 billion, a price-to-earnings ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37.

Institutional Trading of Charles River Laboratories International

A number of large investors have recently added to or reduced their stakes in the company. Canada Pension Plan Investment Board acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $609,000. Jump Financial LLC acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $2,731,000. Ontario Teachers Pension Plan Board acquired a new stake in Charles River Laboratories International in the fourth quarter valued at $405,000. Guggenheim Capital LLC lifted its stake in shares of Charles River Laboratories International by 9.6% during the 4th quarter. Guggenheim Capital LLC now owns 8,253 shares of the medical research company’s stock worth $1,524,000 after buying an additional 725 shares during the last quarter. Finally, Canada Post Corp Registered Pension Plan acquired a new stake in shares of Charles River Laboratories International during the 4th quarter worth about $114,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).